Olivier Wouters
@ojwouters.bsky.social
Associate Professor at Brown University
Investigating global disparities in access to medicines
Investigating global disparities in access to medicines
Reposted by Olivier Wouters
Interesting new @thelancet.bsky.social study by H. Naci @lsehealthpolicy.bsky.social & I. Papanicolas @Brown
Study shows tradeoffs in England of covering costly new drugs at the expense of not covering existing drugs/services in NHS.
Result: Less health gains
www.thelancet.com/journals/lan...
Study shows tradeoffs in England of covering costly new drugs at the expense of not covering existing drugs/services in NHS.
Result: Less health gains
www.thelancet.com/journals/lan...
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis
During 2000–20, NHS coverage of new drugs displaced more population health than it generated. Our results highlight the inherent trade-offs between individuals who directly benefit from new drugs and those who forgo health due to the reallocation of resources towards new drugs.
www.thelancet.com
December 13, 2024 at 12:26 PM
Interesting new @thelancet.bsky.social study by H. Naci @lsehealthpolicy.bsky.social & I. Papanicolas @Brown
Study shows tradeoffs in England of covering costly new drugs at the expense of not covering existing drugs/services in NHS.
Result: Less health gains
www.thelancet.com/journals/lan...
Study shows tradeoffs in England of covering costly new drugs at the expense of not covering existing drugs/services in NHS.
Result: Less health gains
www.thelancet.com/journals/lan...
Reposted by Olivier Wouters
Access to essential medicines is not improving over the past 4 decades with existing tools.
"The gap between richer (high- and upper-middle-income) and poorer (lower-middle- and low-income) countries remained largely unchanged over time."
www.healthaffairs.org/doi/epdf/10....
"The gap between richer (high- and upper-middle-income) and poorer (lower-middle- and low-income) countries remained largely unchanged over time."
www.healthaffairs.org/doi/epdf/10....
December 9, 2024 at 2:55 PM
Access to essential medicines is not improving over the past 4 decades with existing tools.
"The gap between richer (high- and upper-middle-income) and poorer (lower-middle- and low-income) countries remained largely unchanged over time."
www.healthaffairs.org/doi/epdf/10....
"The gap between richer (high- and upper-middle-income) and poorer (lower-middle- and low-income) countries remained largely unchanged over time."
www.healthaffairs.org/doi/epdf/10....
Reposted by Olivier Wouters
Reductions in prices associated with the Medicare Drug Price Negotiation Program differed widely across the 10 drugs. The negotiated prices of all products but 1 remained above list prices in peer countries.
ja.ma/3B9rsXF
ja.ma/3B9rsXF
December 2, 2024 at 8:11 PM
Reductions in prices associated with the Medicare Drug Price Negotiation Program differed widely across the 10 drugs. The negotiated prices of all products but 1 remained above list prices in peer countries.
ja.ma/3B9rsXF
ja.ma/3B9rsXF
Reposted by Olivier Wouters
New paper out at @jamacurrent.bsky.social led by @ojwouters.bsky.social on the empirical assumptions underlying differential protection for biologics & small-molecule drugs.
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
Legal Protections for Biologics vs Small-Molecule Drugs in the US
This Special Communication analyzes and compares development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment...
jamanetwork.com
November 25, 2024 at 5:10 PM
New paper out at @jamacurrent.bsky.social led by @ojwouters.bsky.social on the empirical assumptions underlying differential protection for biologics & small-molecule drugs.
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA).
jamanetwork.com/journals/jam...
Reposted by Olivier Wouters
Relevant to accelerated approval, new DCE from former @portalresearch.org fellow Huseyin Naci et al examined patient views on survival benefit for cancer drugs: "individuals expressed strong preferences for certainty that a cancer drug would offer survival benefit" www.thelancet.com/journals/lan...
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment
Many cancer drugs approved through the FDA's accelerated approval pathway do not offer
any survival benefit to patients. In this study, individuals expressed strong preferences
for certainty that a ca...
www.thelancet.com
November 23, 2024 at 1:19 PM
Relevant to accelerated approval, new DCE from former @portalresearch.org fellow Huseyin Naci et al examined patient views on survival benefit for cancer drugs: "individuals expressed strong preferences for certainty that a cancer drug would offer survival benefit" www.thelancet.com/journals/lan...